魏金莲 副教授/硕士生导师
地址:上海市奉贤区海思路999号华东理工大学实验五楼309室
email:
邮编:200237
个人简介
2017年6月毕业于中国药科大学药学院,获理学博士学位;2017年7月进入华东理工大学药学院承担思政工作;2020年1月进入华东理工大学药学博士后科研流动站从事博士后研究,合作导师为李剑教授。2022年7月出站留校工作,加入cj学者李剑教授团队,从事教学科研工作。
研究方向主要致力于抗肿瘤候选新药的研发,作为主要参与者完成了多个抗肿瘤活性化合物设计合成、药效评价、机制研究的项目,建立了完备的从“体外抗肿瘤表型筛选→机制确证与化学生物学研究→结构修饰与构效关系研究→动物药效与成药性评价”的技术平台体系。近年来,以第一/通讯作者在acta pharm. sin. b、cell death dis.、eur. j. med. chem.等国内外知名学术期刊发表多篇sci文章,申请发明专利4项(授权1项)。入选2020年上海市“超级博士后”激励计划,同年获得国家自然科学基金青年科学基金项目。
教育经历
2012.09–2017.06,中国药科大学,药学院,制药工程学,硕博,导师:尤启冬教授;
2008.09–2012.06,中国药科大学,药学院,制药工程,学士。
工作经历
2024.2-至今,华东理工大学,药学院,副教授;
2022.08–2024.1,华东理工大学,药学院,讲师;
2020.01–2022.07,华东理工大学,药学院,博士后,合作导师:李剑教授;
2017.07–2019.12,华东理工大学,药学院,思政;
主要研究方向
1. 老药新用与老药二次研发
2. 抗肿瘤创新药物的研发与新靶标机制研究
获奖成果
1. 2023年,华东理工大学青年五四奖章(个人)。
2. 2022年,第八届中国国际“互联网﹢”大学生创新创业大赛,国家级铜奖,指导教师。
3. 2022年,第十三届““挑战杯”全国大学生创业计划竞赛,上海赛区银奖,指导教师。
4. 2021年,第七届中国国际“互联网﹢”大学生创新创业大赛,上海赛区银奖,指导教师。
代表性论文(#共同第一作者,*为通讯作者)
1. yumo zhao; yi wan; qiyang yuan; jinlian wei*; yongqiang zhang*. photocatalytic c−si bond formations using pentacoordinate silylsilicates as silyl radical precursors: synthetic tricks using old reagents, org. lett. 2023, 25: 1386-1391.
2. jinlianwei#, yongyun li#,ruoxi li, xin chen, tiannuo yang, liang liao, yuqingxie, jin zhu, fei mao, renbing jia*, xiaofang xu*, jian li*. drug repurposing of propafenone to discover novel anti-tumor agents by impairing homologous recombination to delay dna damage recovery of rare disease conjunctival melanoma. eur. j. med. chem. 2023, 250, 115238.
3. jinlian wei#, xin chen#, yongyun li#, ruoxi li, keting bao, liang liao, yuqing xie, tiannuo yang, jin zhu, fei mao, shuaishuai ni, renbing jia*, xiaofang xu*, jian li*. cucurbitacin b-induced g2/m cell cycle arrest of conjunctival melanoma cells mediated by grp78-foxm1-kif20a pathway. acta pharm. sin. b. 2022, 12(10):3861-3876.
#, xi yang#, fei mao#, jinlian wei#, yixiang xu, baoli li, jin zhu, shuaishuai ni*, lijun jia*, jian li*. development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and in vivo. eur. j. med. chem. 2021, 210, 112964.
, yingrui yang, mengchen lu, yonghua lei, lili xu, zhengyu jiang, xiaoli xu, xiaoke guo, xiaojin zhang, haopeng sun*, qidong you, recent advances in the discovery of hif-1alpha-p300/cbp inhibitors as anti-cancer agents. mini-rev. med. chem. 2018, 18 (4), 296-309.
7. jinlian wei, yingrui yang, yali li, xiaofei mo, xiaoke guo, xiaojin zhang, xiaoli xu, zhengyu jiang, qidong you*, synthesis and evaluation of n-(benzofuran-5-yl)aromaticsulfonamide derivatives as novel hif-1 inhibitors that possess anti-angiogenic potential, bioorg.med. chem. 2017, 25 (6): 1737-1746.
8. xiaoli xu, yingrui yang, xiaofei mo, jinlian wei, xiaojin zhang, qidong you*, design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via in terfering the hypoxia environment by targeting hif-1alpha pathway, eur. j. med. chem. 2017, 137: 45-62.
9. jinlian wei, yingrui yang, mengchen lu, lili xu, fang liu, zhenwei yuan, qichao bao, zhengyu jiang, xiaoli xu, xiaoke guo, xiaojin zhang, qidong you*, haopeng sun*, escape, or vanish: control the fate of p53 through mdm2-mediated ubiquitination. anticancer agents med. chem. 2015, 16 (2): 174-189.
10. yingrui yang, jinlian wei, xiaofei mo, zhenwei yuan, jialing wang, chao zhang, yieyue xie, qidong you*, haopeng sun*, discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of hif-1 pathway. bioorg med chem lett.2016, 26 (11): 2713-2718.
11. xin xue, jinlian wei, lili xu, meiyang xi, xiaoli xu, fang liu, xiaoke guo, lei wang, xiaojin zhang, mingye zhang, mengchen lu, haopeng sun*, qidong you*, effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-mdm2 interaction inhibitors. j chem inf model.2013, 53 (10): 2715-2729.